Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EV/FCF ratio high or low?
The EV/FCF ratio of 23.10x is 15% above its 5-year average of 20.12x, near the high end of its 5-year range (15.33x–24.00x).
25.14% above its 12-month average of 18.46x.
Reported annual fiscal-period values; no daily interpolation.
EV/FCF RATIO
23.10x
EV/FCF RATIO AVG TTM
18.46x
EV/FCF RATIO AVG 3Y
18.78x
EV/FCF RATIO AVG 5Y
20.12x
EV/FCF RATIO AVG 10Y
18.76x
EV/FCF RATIO AVG 15Y
17.78x
EV/FCF RATIO AVG 20Y
18.86x
CURRENT VS TTM AVG
+25.14%
CURRENT VS 3Y AVG
+22.99%
CURRENT VS 5Y AVG
+14.79%
CURRENT VS 10Y AVG
+23.13%
CURRENT VS 15Y AVG
+29.95%
CURRENT VS 20Y AVG
+22.48%
SECTOR MEDIAN · HEALTHCARE
26.38x
median of 81 covered companies
CURRENT VS SECTOR MEDIAN
-12.43%
vs the sector median at left
Roche Holding AG
Market Cap
$359.46B
EV/FCF Ratio
23.10x
TTM Avg
18.46x
3Y Avg
18.78x
5Y Avg
20.12x
Market Cap
$358.76B
EV/FCF Ratio
17.05x
TTM Avg
19.29x
3Y Avg
29.59x
5Y Avg
26.14x
Market Cap
$369.34B
EV/FCF Ratio
26.49x
TTM Avg
22.49x
3Y Avg
23.01x
5Y Avg
23.33x
Market Cap
$234.38B
EV/FCF Ratio
37.23x
TTM Avg
36.66x
3Y Avg
34.10x
5Y Avg
35.09x
Market Cap
$205.42B
EV/FCF Ratio
30.06x
TTM Avg
36.20x
3Y Avg
44.44x
5Y Avg
39.70x
Market Cap
$193.04B
EV/FCF Ratio
25.96x
TTM Avg
28.98x
3Y Avg
34.54x
5Y Avg
30.92x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Roche Holding AG (RHHBY) | $359.46B | 23.10x | 18.46x | 18.78x | 20.12x |
| UnitedHealth Group Incorporated (UNH)vs › | $358.76B | 17.05x | 19.29x | 29.59x | 26.14x |
| Merck & Co., Inc. (MRK)vs › | $369.34B | 26.49x | 22.49x | 23.01x | 23.33x |
| AbbVie Inc. (ABBV)vs › | $455.87B | 26.92x | 23.61x | 20.85x | 18.21x |
| AstraZeneca PLC (AZN)vs › | $255.15B | 32.80x | 35.01x | 35.07x | 37.59x |
| Amgen Inc. (AMGN)vs › | $235.85B | 27.80x | 24.17x | 25.54x | 22.94x |
| Thermo Fisher Scientific Inc. (TMO)vs › | $234.38B | 37.23x | 36.66x | 34.10x | 35.09x |
| Novo Nordisk A/S (NVO)vs › | $205.42B | 30.06x | 36.20x | 44.44x | 39.70x |
| Abbott Laboratories (ABT)vs › | $193.04B | 25.96x | 28.98x | 34.54x | 30.92x |
| Gilead Sciences, Inc. (GILD)vs › | $184.82B | 15.69x | 18.58x | 16.25x | 14.67x |
EV/FCF
23.1x
P/FCF
21.3x
FCF Yield
4.69%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/FCF RATIO |
|---|---|
| 2025-12-31 | 21.59x |
| 2024-12-31 | 15.33x |
| 2023-12-31 | 19.23x |
| 2022-12-31 | 18.98x |
| 2021-12-31 | 21.61x |
| 2020-12-31 | 24.00x |
| 2019-12-31 | 14.77x |
| 2018-12-31 | 13.87x |
| 2017-12-31 | 15.52x |
| 2016-12-31 | 19.90x |
| 2015-12-31 | 21.56x |
| 2014-12-31 | 19.39x |
| 2013-12-31 | 17.30x |
| 2012-12-31 | 13.78x |
| 2011-12-31 | 14.76x |
| 2010-12-31 | 12.82x |
| 2009-12-31 | 13.91x |
| 2008-12-31 | 16.27x |
| 2007-12-31 | 23.32x |
| 2006-12-31 | 30.84x |
| 2005-12-31 | 27.31x |
| 2004-12-31 | 24.56x |
| 2003-12-31 | 24.15x |
| 2001-12-31 | 26.64x |
| 2000-12-31 | 66.42x |
| 1998-12-31 | 108.85x |
